FGFR3-TACC3: A novel gene fusion in cervical cancer

Benedito A. Carneiro*, Julia A. Elvin, Suneel D. Kamath, Siraj M. Ali, Ajit S. Paintal, Alvaro Restrepo, Emily Berry, Francis J. Giles, Melissa L. Johnson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


Cervical cancer epitomizes the success of cancer prevention through the human papillomavirus (HPV) vaccine, but significant challenges remain in the treatment of advanced disease. We report the first three cases of cervical carcinoma harboring an FGFR3-TACC3 fusion, which serves as a novel therapeutic target. The fusion, identified by comprehensive genomic profiling, activates the FGFR pathway that has been implicated in HPV-driven carcinogenesis. One of the patients whose tumor contained the FGFR3-TACC3 fusion was treated with an investigational FGFR tyrosine kinase inhibitor. Concomitant molecular alterations involving the PI3K/AKT/mTOR and RAF/MEK pathways were also identified and suggest other treatment strategies that deserve investigation. This case series highlights the role of comprehensive genomic profiling in the identification of new therapeutic targets and in targeted therapy selection for patients with cervical cancer.

Original languageEnglish (US)
Pages (from-to)53-56
Number of pages4
JournalGynecologic Oncology Reports
StatePublished - Aug 1 2015


  • Adenocarcinoma of the cervix
  • Cervical carcinoma
  • FGFR inhibitors
  • FGFR translocations
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology


Dive into the research topics of 'FGFR3-TACC3: A novel gene fusion in cervical cancer'. Together they form a unique fingerprint.

Cite this